Why the study?
Bleeding is the commonest and most concerning adverse event with anticoagulants, and guidance is needed on specific antidotes indicated for severe or life-threatening DOAC-associated bleeding.
How should specific DOAC reversal agents be used for managing severe or life-threatening bleeding?
How should specific DOAC reversal agents be used for managing severe or life-threatening bleeding?
This review provides practical guidance on the indications, dosing, and potential side effects of specific DOAC reversal agents for managing severe or life-threatening bleeding.
Answers are grounded in this paper and cite their sources.
May guide reversal agent selection in severe DOAC bleeding; leaves open need for prospective outcome trials.
Bleeding is the commonest and most concerning adverse event associated with anticoagulants. Bleeding, depending on the severity, is managed in various ways, and for severe or life-threatening bleeding, specific antidotes are indicated and recommended. This review provides guidance relating to specific direct oral anticoagulant (DOAC) reversal agents, the antidotes. We discuss their indications for use, dosing, and potential side effects.
No takes yet. Share an insight, caveat, or question.
White et al. (2022) conducted a review in DOAC-associated bleeding. DOAC reversal agents (Andexanet alfa, Idarucizumab) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: